Industry watchers are watching closely for heart safety data in the nondialysis population after roxadustat and vadadustat encountered problems.
by Angus Liu Nov 5, 2021, 1:30 PM
GSK’s anemia drug succeeds where AZ-FibroGen, Akebia failed
with
no comment